Preview

Cardiovascular Therapy and Prevention

Advanced search

DYNAMICS OF CARDIOVASCULAR STATUS AND SERUM MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, TREATED WITH INFLIXIMAB

https://doi.org/10.15829/1728-8800-2013-2-80-84

Abstract

Aim. To assess the complex dynamics of the main parameters of cardiovascular status and serum markers of endothelial dysfunction (ED) in patients with rheumatoid arthritis (RA), who were treated with infliximab.

Material and methods. The main group (MG) included 50 patients with seropositive RA, who received a combination of methotrexate and infliximab. The examination took place at baseline, as well as two, six, and 14 weeks after the treatment started. Comparison groups (CG) included healthy volunteers (n=25) and RA patients treated with methotrexate only (n=110). Serum levels of tumor necrosis factor-α (TNO-α), interleukin-10 (IL-10), tissue plasminogen activator (TPA), and von Willebrand factor (vWf) were measured, using ELISA. Left ventricular (LV) function and microvascular status were assessed with echocardiography and laser Doppler flowmetry (LDF), respectively.

Results. The E/A ratio was reduced in all subgroups, and at Week 14 of infliximab therapy, it slightly increased. At baseline, LDF parameters, such as neurogenic arteriole tone and intravascular resistance, were increased. Infliximab therapy was associated with a moderate decline of these parameters. Throughout the study, serum vWf concentration was higher in MG patients than in healthy controls. TPA activity was reduced at baseline (496±173 pg/ml), increasing at Week 14 up to 705±157 pg/ml. Baseline concentrations of TNF-α and UL-10 were substantially elevated (357,1±34 and 453±42 pg/ml, respectively). At Week 6, TNF-α concentration decreased significantly. At Week 14, not only TNF-α level decreased, reaching 94±28 pg/ml, but also the ratio TNF-α/IL-10 decreased (from 0,78±0,5 to 0,4±0,2).

Conclusion. In RA patients, infliximab was highly effective for the functional cytokine dysbalance correction, also demonstrating pleiotropic effects, such as correction of microvascular and endothelial dysfunction. 

About the Authors

S. P. Oranskyi
Kuban State Medical University, Krasnodar
Russian Federation


L. N. Eliseeva
Kuban State Medical University, Krasnodar
Russian Federation


N. A. Samorodskaya
Kuban State Medical University, Krasnodar
Russian Federation


I. G. Malkhasyan
Kuban State Medical University, Krasnodar
Russian Federation


References

1. Demographic Yearbook of Russia 2009: Statistical Yearbook. Surinov AE editor. Moscow: Rosstat, 2009; 557 p. Russian (Демографический ежегодник России 2009: Статистический сборник. Под ред. А. Е. Суринова. M.: Росстат 2009; 557 c).

2. Krupatkin AI, Sidorov VV. Laser Doppler flowmetry of blood microcirculation. Moscow: Medicine 2005; pp.49–79. Russian (Крупаткин А. И., Сидоров В. В. Лазерная доплеровская флоуметрия микроциркуляции крови. М.: Медицина 2005; 49–79).

3. Makolkin VI. Microcirculation in cardiology. Moscow: Vizart 2004; 247 p. Russian (Маколкин В. И. Микроциркуляция в кардиологии. М: Визарт 2004; 247 с).

4. Malaya LT, Korzh AN, Valkovaja LB. Endothelial dysfunction in the pathology of the cardiovascular system. Kharkov: Torsing 2000; 427 p. Russian (Малая Л. Т., Корж А. Н., Валковая Л. Б. Эндотелиальная дисфункция при патологии сердечно-сосудистой системы. Харьков: Торсинг 2000; 427 с).

5. Oganov RG, Shalnova SA, Kalinina AM. Prevention of cardiovascular diseases. Moscow: Geotar-Media 2009; 216 p. Russian (Оганов Р. Г., Шальнова С. А., Калинина А. М. Профилактика сердечно-сосудистых заболеваний. М.: Гэотар-Медиа 2009; 216 с).

6. Oranskiy SP, Yeliseyeva LN, Vasinova YV, et al. Anemia of chronic inflammation, cytokine status and left ventricular dysfunction in patients with rheumatoid arthritis. Kuban Medical Research Journal 2009; 1 (106):76–9. Russian (Оранский С. П., Елисеева Л. Н., Васинова Ю. В. и др. Анемия хронического воспаления, цитокиновый профиль и дис- функция левого желудочка у больных ревматоидным артритом. Куб науч мед вест 2009; 1 (106): 76–9).

7. Podzolkov VI, Bulatov VA. Microcirculatory disorders in arterial hypertension: a cause, a sequence or another «vicious circle»? Heart 2005; 3 (21):132–7. Russian (Подзолков В. И., Булатов В. А. Нарушения микроциркуляции при артериальной гипертензии: причина, следст- вие или еще один «порочный круг»? Сердце 2005; 3 (21): 132–7).

8. Rheumatogy: National Guidelines. Nassonov E. L., Nassonova V. A. editors. M.: Geotar-Media 2008; 720 p. Russian (Ревматология: национальное руководство. Под ред. Е. Л. Насонова, В. А. Насоновой. М.: Гэотар- Медиа 2008; 720 с)

9. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634–43.

10. Foster W, Carruthers D, Lip GY, et al. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment. J Thromb Thrombolysis 2009; 29 (4): 437– 42.

11. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007; 32 (7): 568–72.

12. Hürlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation2002; 106 (17): 2184–7.

13. Irace C, Mancuso G, Fiaschi E, et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis2004; 177 (1): 113–8.

14. Jin T, Bokarewa M, Amu S, et al. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol 2009; 27 (3): 491–4.

15. Kerekes G, Szekanecz Z, Der H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008; 35: 398–406.

16. Kerekes G, Soltész P, Dér H, et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009; 1173: 814–21.

17. Kombe B. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34–45.

18. Saag KG. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762–84.

19. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity I n rheumatic diseases Vascular Health and Risk Management 2008; 4 (3): 605–14.


Review

For citations:


Oranskyi S.P., Eliseeva L.N., Samorodskaya N.A., Malkhasyan I.G. DYNAMICS OF CARDIOVASCULAR STATUS AND SERUM MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, TREATED WITH INFLIXIMAB. Cardiovascular Therapy and Prevention. 2013;12(2):80-84. (In Russ.) https://doi.org/10.15829/1728-8800-2013-2-80-84

Views: 581


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)